Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30624470 | 1.00 | ALOX15 (0.31) | ALOX15ALDH1A1MAPK10HSD17B10KDM4E | |
| SCHEMBL220456 | 0.71 | — | — | |
| SCHEMBL9940454 | 0.71 | — | — | |
| SCHEMBL31408049 | 0.68 | MEN1 (0.32) | ALDH1A1 | |
| SCHEMBL4513308 | 0.67 | — | — | |
| SCHEMBL29412638 | 0.67 | — | — | |
| SCHEMBL4237139 | 0.67 | — | — | |
| SCHEMBL26658123 | 0.65 | — | — | |
| SCHEMBL29569587 | 0.65 | MEN1 (0.30) | ALDH1A1 | |
| SCHEMBL44493 | 0.65 | MEN1 (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 752 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110183397-B | Method for preparing 1, 5-benzothiazine compound by catalysis of zirconocene dichloride | 陕西师范大学 | 2022-08-23 | — | — | CN | claimed |
| WO-2015173035-A1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2015-11-19 | — | — | WO | claimed |
| US-8288529-B2 | Geometric synthesis of porphyrin rods | NORTH CAROLINA STATE UNIVERSITY (US) | 2012-10-16 | — | — | US | claimed |
| US-8207329-B2 | Synthesis of chlorins and phorbines with enhanced red spectral features | NORTH CAROLINA STATE UNIVERSITY (US) | 2012-06-26 | — | — | US | claimed |
| US-7799910-B2 | Geometric synthesis of porphyrin rods | NORTH CAROLINA STATE UNIVERSITY (US) | 2010-09-21 | — | — | US | claimed |
| EP-1317443-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-01-14 | — | — | EP | claimed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | claimed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | claimed |
| US-20050026942-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2005-02-03 | — | — | US | claimed |
| EP-1317443-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | claimed |
| US-20020147192-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2002-10-10 | — | — | US | claimed |
| WO-2002022599-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | claimed |
| EP-0227932-A1 | Novel fused pyridine compounds, intermediates for the preparation of, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1987-07-08 | — | — | EP | claimed |
| EP-4735535-A2 | COMPOUNDS INCLUDING A WATER-SOLUBILIZATION MOTIF AND METHODS OF USE THEREOF | North Carolina State University (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4705295-A2 | MULTIFUNCTIONAL COMPOUND CORE FOR ACTIVE AGENTS AND USES THEREOF | The University of North Carolina at Chapel Hill (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705400-A1 | ADSORPTIVE COATINGS FOR METAL SURFACES AND RELATED METHODS | Research Triangle Institute (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-0227932-B1 | NOVEL FUSED PYRIDINE COMPOUNDS, INTERMEDIATES FOR THE PREPARATION OF, AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | AMERICAN CYANAMID COMPANY (US) | 1993-01-13 | — | — | EP | disclosed |
| EP-0227932-A1 | Novel fused pyridine compounds, intermediates for the preparation of, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1987-07-08 | — | — | EP | disclosed |
| CN-85103524-A | Process for preparing 1, 5-benzothiazine derivatives | — | 1986-11-05 | — | — | CN | disclosed |
| CN-85103524-A | Process for preparing 1, 5-benzothiazine derivatives | — | 1986-11-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147192-A1 | Chemokine receptor binding heterocyclic compounds | CCR2, CXCR3, ACKR3 | ALOX15 1853/4885ALDH1A1 1950/4885MAPK10 1517/4885 |
| US-20070123510-A1 | Guanidine derivatives | NPFFR1, NPFFR2, OGFR | ALOX15 3362/4885ALDH1A1 2183/4885MAPK10 925/4885 |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | CCR2, CXCR3, ACKR3 | ALOX15 1853/4885ALDH1A1 1950/4885MAPK10 1517/4885 |
| US-20050026942-A1 | Chemokine receptor binding heterocyclic compounds | CCR2, CXCR3, ACKR3 | ALOX15 1853/4885ALDH1A1 1950/4885MAPK10 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.